

Naval G Daver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1006749/publications.pdf>

Version: 2024-02-01

274
papers

15,605
citations

22153

59
h-index

24982

109
g-index

279
all docs

279
docs citations

279
times ranked

12489
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. <i>Blood Advances</i> , 2023, 7, 828-831.	5.2	1
2	SOHO State of the Art Updates and Next Questions: Harnessing Apoptosis in AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 133-139.	0.4	4
3	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. <i>Blood</i> , 2022, 139, 907-921.	1.4	34
4	Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	4.1	25
5	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2022, 139, 1098-1110.	1.4	46
6	Improved survival of patients with myelofibrosis in the last decade: Single-center experience. <i>Cancer</i> , 2022, , .	4.1	16
7	Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 43-50.	2.0	1
8	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	6.2	48
9	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. <i>Journal of Hematology and Oncology</i> , 2022, 15, 12.	17.0	13
10	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	5.2	17
11	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. <i>Blood Cancer Journal</i> , 2022, 12, 23.	6.2	4
12	Improved outcomes among newly diagnosed patients with <i>FMS-like tyrosine kinase 3 internal tandem duplication</i> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	4.1	15
13	Gilteritinib clinical activity in relapsed/refractory <i>FLT3</i> mutated acute myeloid leukemia previously treated with <i>FLT3</i> inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 322-328.	4.1	21
14	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). <i>Blood Cancer Journal</i> , 2022, 12, 5.	6.2	49
15	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 574-582.	4.1	9
16	A nonstick marrow may help to fry leukemia. <i>Blood</i> , 2022, 139, 1119-1121.	1.4	0
17	Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. <i>Blood Advances</i> , 2022, 6, 5546-5549.	5.2	1
18	Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	4.1	33

#	ARTICLE	IF	CITATIONS
19	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	4.1	12
20	<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72.	1.4	46
21	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	4.1	4
22	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	1.3	12
23	Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 2736-2745.	4.1	8
24	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	4.6	26
25	Hypomethylating agent and venetoclax with FLT3 inhibitor <i>ætriplet</i> therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	6.2	33
26	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014.	5.2	37
27	Lenalidomide promotes the development of <i>TP53</i> -mutated therapy-related myeloid neoplasms. <i>Blood</i> , 2022, 140, 1753-1763.	1.4	56
28	Venetoclax combined with <i>FLAG-IDA</i> induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	4.1	31
29	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. <i>Nature Medicine</i> , 2022, 28, 1212-1223.	30.7	104
30	Resistance to targeted therapies: delving into FLT3 and IDH. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	9
31	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	1.6	41
32	Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti- <i>PD-L1</i>) in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2711-2714.	1.3	6
33	Venetoclax Plus Gilteritinib for <i>FLT3</i> -Mutated Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 4048-4059.	1.6	73
34	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1755-1763.	5.8	48
35	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53.	4.1	8
36	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	4.1	59

#	ARTICLE	IF	CITATIONS
37	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	5.0	50
38	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	4.1	19
39	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 Δ ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	4.1	10
40	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. <i>Cancer</i> , 2021, 127, 1894-1900.	4.1	5
41	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>NPM1</i> mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	2.5	28
42	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	6.2	85
43	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
44	Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41.	6.2	313
45	Decitabine and venetoclax for <i>IDH1/2</i> mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	4.1	19
46	An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 89-96.	2.3	8
47	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	6.2	5
48	Immune checkpoint inhibitors in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101247.	1.7	15
49	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387.	2.8	39
50	A Phase I dose-escalation study of <i>DCLL9718S</i> , an antibody-drug conjugate targeting <i>C-type lectin-like molecule 1</i> (<i>CLL1</i>) in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E175-E179.	4.1	3
51	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	4.1	24
52	Taking aim at IDH in fitter patients with AML. <i>Blood</i> , 2021, 137, 1706-1707.	1.4	0
53	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<i>MDS/MPN-RS-T</i>) and myelodysplastic syndrome with ring sideroblasts (<i>MDS-RS</i>). <i>American Journal of Hematology</i> , 2021, 96, E246-E249.	4.1	9
54	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	5.2	35

#	ARTICLE	IF	CITATIONS
55	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. <i>Blood Advances</i> , 2021, 5, 2156-2164.	5.2	33
56	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130.	3.5	34
57	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499.	4.1	34
58	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	4.1	5
59	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	4.1	33
60	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647.	4.1	15
61	An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232.	4.1	17
62	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56
63	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. <i>Blood Cancer Journal</i> , 2021, 11, 98.	6.2	24
64	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. <i>Leukemia</i> , 2021, 35, 1843-1863.	7.2	123
65	FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. <i>American Journal of Hematology</i> , 2021, 96, E275-E279.	4.1	3
66	Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 67-71.	1.4	21
67	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	4.1	23
68	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	4.1	13
69	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
70	FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. <i>Blood Cancer Journal</i> , 2021, 11, 104.	6.2	61
71	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	1.4	31
72	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	4.1	34

#	ARTICLE	IF	CITATIONS
73	Postâ€transplantation donorâ€derived Sezary syndrome in a patient with <scp>A91V <i>PRF1</i></scp> variant hemophagocytic lymphohistiocytosis. American Journal of Hematology, 2021, 96, E350-E353.	4.1	2
74	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. Journal of Hematology and Oncology, 2021, 14, 94.	17.0	19
75	A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules. Statistics in Medicine, 2021, 40, 4629-4639.	1.6	0
76	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood, 2021, 138, 1733-1739.	1.4	19
77	Outcomes in patients with newly diagnosed <i>TP53</i>â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551.	4.1	40
78	Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML. , 2021, 9, e002968.		21
79	Outcomes of <i>TP53</i>â€mutant acute myeloid leukemia with decitabine and venetoclax. Cancer, 2021, 127, 3772-3781.	4.1	80
80	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Advances, 2021, 5, 3163-3173.	5.2	17
81	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e552-e561.	4.6	81
82	Phase II study of single-agent nivolumab in patients with myelofibrosis. Annals of Hematology, 2021, 100, 2957-2960.	1.8	11
83	Development of <scp><i>TP53</i></scp> mutations over the course of therapy for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 1420-1428.	4.1	10
84	Phase II study of azacitidine with pembrolizumab in patients with intermediateâ€ or higherâ€risk myelodysplastic syndrome. British Journal of Haematology, 2021, 195, 378-387.	2.5	32
85	Tenâ€day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity scoreâ€matched analysis. Cancer, 2021, 127, 4213-4220.	4.1	24
86	AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S290.	0.4	40
87	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162.	6.2	32
88	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. Blood Advances, 2021, 5, 5415-5419.	5.2	24
89	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leukemia and Lymphoma, 2021, , 1-5.	1.3	2
90	Gilteritinib combination therapies in pediatric patients with <i>FLT3</i>-mutated acute myeloid leukemia. Blood Advances, 2021, 5, 5215-5219.	5.2	9

#	ARTICLE	IF	CITATIONS
91	Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5739-5741.	7.0	3
92	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	1.6	173
93	Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. <i>Blood Advances</i> , 2021, 5, 4569-4574.	5.2	15
94	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	12.8	44
95	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2021, 8, e922-e933.	4.6	27
96	Infectious complications among patients with AML treated with immune checkpoint inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, . .	0.4	3
97	Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 691-691.	1.4	11
98	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 273-295.	1.6	1
99	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 800110.	2.8	7
100	Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. <i>Haematologica</i> , 2020, 105, 697-707.	3.5	78
101	CPX-351 (vyxeos) in AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 288-297.	1.3	63
102	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <i>Journal of Hematology and Oncology</i> , 2020, 13, 132.	17.0	18
103	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	4.6	201
104	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. <i>Cancer</i> , 2020, 126, 4322-4331.	4.1	19
105	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	4.1	28
106	Phase 1 study of combinatorial sorafenib, <sc>G-CSF</sc>, and plerixafor treatment in relapsed/refractory, <sc>FLT3-ITD</sc>-mutated acute myelogenous leukemia patients. <i>American Journal of Hematology</i> , 2020, 95, 1296-1303.	4.1	22
107	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	4.6	43
108	Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	5.2	37

#	ARTICLE	IF	CITATIONS
109	New directions for emerging therapies in acute myeloid leukemia: the next chapter. <i>Blood Cancer Journal</i> , 2020, 10, 107.	6.2	96
110	Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series. <i>Frontiers in Oncology</i> , 2020, 10, 588876.	2.8	13
111	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). <i>American Journal of Hematology</i> , 2020, 95, E326-E329.	4.1	2
112	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. <i>American Journal of Hematology</i> , 2020, 95, E313-E315.	4.1	4
113	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	5.2	29
114	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 5681-5689.	5.2	105
115	Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 562558.	2.8	49
116	A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101220.	1.7	3
117	Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. <i>American Journal of Hematology</i> , 2020, 95, E225-E228.	4.1	9
118	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882.	0.4	10
119	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	4.1	10
120	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.2	37
121	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	4.1	51
122	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 2193-2205.	4.1	33
123	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. <i>Cancer Discovery</i> , 2020, 10, 506-525.	9.4	212
124	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1690-1699.	5.2	4
125	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	1.4	53
126	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. <i>Blood</i> , 2020, 135, 449-452.	1.4	39

#	ARTICLE	IF	CITATIONS
127	A bispecific approach to improving CAR T cells in AML. <i>Blood</i> , 2020, 135, 703-704.	1.4	7
128	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	5.2	86
129	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	5.2	106
130	Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. <i>Frontiers in Immunology</i> , 2020, 11, 590494.	4.8	21
131	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 18-20.	1.4	17
132	Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 11-12.	1.4	4
133	Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. <i>Blood</i> , 2020, 136, 53-55.	1.4	8
134	Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. <i>Blood</i> , 2020, 136, 30-33.	1.4	3
135	Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study. <i>Blood</i> , 2020, 136, 20-22.	1.4	23
136	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2020, 136, 11-13.	1.4	16
137	Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. <i>Blood</i> , 2020, 136, 19-20.	1.4	18
138	Hemophagocytic Lymphohistiocytosis in the Cancer Patient. , 2020, , 1155-1161.		0
139	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3 internal tandem duplication mutation positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	4.1	38
140	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e480-e488.	4.6	103
141	Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. <i>Cancer Management and Research</i> , 2019, Volume 11, 8817-8828.	1.9	23
142	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	4.1	20
143	Phase 1/2 study of DFP10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1665-1673.	4.1	5
144	From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. <i>Drugs</i> , 2019, 79, 1177-1186.	10.9	8

#	ARTICLE	IF	CITATIONS
145	AML: The future is now or was it yesterday?. Best Practice and Research in Clinical Haematology, 2019, 32, 115.	1.7	0
146	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer, 2019, 125, 3219-3224.	4.1	14
147	Prognostic significance of baseline <i>FLT3</i> mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	4.1	32
148	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2019, 125, 2579-2586.	4.1	63
149	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. International Journal of Hematology, 2019, 109, 545-552.	1.6	25
150	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 2019, 94, E188-E190.	4.1	4
151	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American Journal of Hematology, 2019, 94, 803-811.	4.1	51
152	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Therapeutic Advances in Hematology, 2019, 10, 204062071982731.	2.5	93
153	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Advances, 2019, 3, 1533-1539.	5.2	9
154	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology, the, 2019, 6, e29-e37.	4.6	84
155	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	9.4	380
156	Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia, 2019, 33, 299-312.	7.2	625
157	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1.	17.0	257
158	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with <i>NPM1</i> and <i>FLT3</i> internal tandem duplication genotypes. Cancer, 2019, 125, 1091-1100.	4.1	50
159	The distribution of T cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481.	4.1	229
160	Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edged Sword. Biology of Blood and Marrow Transplantation, 2019, 25, e1-e2.	2.0	10
161	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacitidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2647-2647.	1.4	11
162	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood, 2019, 134, 229-229.	1.4	30

#	ARTICLE	IF	CITATIONS
163	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	1.4	34
164	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). <i>Blood</i> , 2019, 134, 290-290.	1.4	19
165	The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. <i>Blood</i> , 2019, 134, 569-569.	1.4	161
166	Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study. <i>Blood</i> , 2019, 134, 3910-3910.	1.4	34
167	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	1.4	15
168	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMG632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2601-2601.	1.4	7
169	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	1.4	9
170	Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML. <i>Blood</i> , 2019, 134, 1428-1428.	1.4	5
171	Clinical Profile of IMG632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2019, 134, 734-734.	1.4	40
172	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. <i>Blood</i> , 2019, 134, 2582-2582.	1.4	2
173	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. <i>Blood</i> , 2019, 134, 830-830.	1.4	38
174	Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2640-2640.	1.4	12
175	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1094-1105.	7.2	164
176	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018, 124, 2534-2540.	4.1	23
177	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2018, 124, 2758-2765.	4.1	78
178	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , 2018, 19, 240-248.	10.7	192
179	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2238-2241.	1.3	20
180	Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	4.1	23

#	ARTICLE	IF	CITATIONS
181	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	1.3	90
182	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	4.1	74
183	Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	27.6	1,659
184	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	4.1	68
185	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	4.1	57
186	Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	4.1	336
187	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	4.1	54
188	Myeloid/lymphoid neoplasms with <i>FGFR1</i> rearrangement. <i>Leukemia and Lymphoma</i> , 2018, 59, 1672-1676.	1.3	53
189	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	1.6	156
190	Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 97-116.	1.6	18
191	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e618-e627.	4.6	190
192	Mutational landscape of myelodysplastic/myeloproliferative neoplasm – unclassifiable. <i>Blood</i> , 2018, 132, 2100-2103.	1.4	40
193	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	1.4	62
194	Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E202.	4.1	116
195	Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. <i>Haematologica</i> , 2018, 103, 1642-1653.	3.5	33
196	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated <i>FLT3</i> Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	4.1	95
197	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with <i>FLT3</i> internal tandem duplication and worse relapse-free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383.	4.1	17
198	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	4.6	66

#	ARTICLE	IF	CITATIONS
199	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. <i>Current Opinion in Hematology</i> , 2018, 25, 136-145.	2.5	73
200	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286.	1.4	19
201	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2018, 132, 36-36.	1.4	12
202	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 905-905.	1.4	21
203	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 465-465.	1.4	48
204	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Oncotarget</i> , 2018, 9, 9714-9727.	1.8	56
205	Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. <i>American Journal of Managed Care</i> , 2018, 24, S347-S355.	1.1	20
206	Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. <i>American Journal of Managed Care</i> , 2018, 24, S356-S365.	1.1	15
207	Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. <i>BBA Clinical</i> , 2017, 7, 36-40.	4.1	13
208	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 20-34.	4.4	105
209	Malignancy-associated haemophagocytic lymphohistiocytosis in adults. <i>Lancet Oncology, The</i> , 2017, 18, 169-171.	10.7	16
210	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 845-850.	4.1	36
211	A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. <i>Cancer</i> , 2017, 123, 3229-3240.	4.1	155
212	“JAK”ing™ up the treatment of primary myelofibrosis. <i>Current Opinion in Hematology</i> , 2017, 24, 115-124.	2.5	8
213	Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 73-95.	1.6	31
214	Poor outcomes associated with +der(22)t(9;22) and $\hat{9}/9p$ in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	4.1	41
215	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283.	1.4	214
216	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 331-337.	4.1	39

#	ARTICLE	IF	CITATIONS
217	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S3.	0.4	10
218	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 897-901.	0.4	127
219	Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. <i>European Journal of Haematology</i> , 2017, 99, 536-543.	2.2	20
220	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	4.1	37
221	FLT3 inhibition in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2017, 18, 988-989.	10.7	7
222	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	4.1	114
223	Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S105-S110.	0.4	52
224	Immunotherapy based approaches in myelofibrosis. <i>Expert Review of Hematology</i> , 2017, 10, 903-914.	2.2	12
225	Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. <i>Lancet Oncology</i> , The, 2017, 18, 1571-1573.	10.7	19
226	Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. <i>Blood</i> , 2017, 130, 1125-1131.	1.4	180
227	Adult cancer-related hemophagocytic lymphohistiocytosis – a challenging diagnosis: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 172.	0.8	2
228	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. <i>Leukemia and Lymphoma</i> , 2017, 58, 866-871.	1.3	4
229	Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. <i>American Journal of Hematology</i> , 2017, 92, 7-11.	4.1	41
230	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	4.1	49
231	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 426-435.	4.1	63
232	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	5.2	83
233	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. <i>Leukemia Research</i> , 2017, 59, 110-116.	0.8	53
234	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. <i>Blood</i> , 2017, 130, 723-723.	1.4	35

#	ARTICLE	IF	CITATIONS
235	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 815-815.	1.4	11
236	Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. <i>Cancer</i> , 2016, 122, 2857-2866.	4.1	88
237	Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL. <i>Blood</i> , 2016, 128, 1316-1317.	1.4	11
238	Targeting Immune Checkpoints in Hematologic Malignancies. <i>Pharmacological Reviews</i> , 2016, 68, 1014-1025.	16.0	36
239	Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	4.1	156
240	<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	4.1	200
241	Philadelphia-positive dimorphic blasts in mixed phenotype acute leukemia with <i>TET2</i> mutation. <i>American Journal of Hematology</i> , 2016, 91, 647-648.	4.1	1
242	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 769-777.	0.7	39
243	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. <i>Expert Review of Hematology</i> , 2016, 9, 433-445.	2.2	9
244	Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML)., 2016, , .		7
245	Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (>65 yrs) with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1639-1639.	1.4	14
246	Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 2900-2900.	1.4	35
247	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. <i>Blood</i> , 2016, 128, 3171-3171.	1.4	2
248	A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 344-344.	1.4	60
249	Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 763-763.	1.4	53
250	Clinical implications of <i>TP53</i> mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187.	1.8	86
251	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015, 90, 276-281.	4.1	139
252	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 653-661.	3.5	191

#	ARTICLE	IF	CITATIONS
253	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> ,the, 2015, 2, e186-e193.	4.6	227
254	Outcome of patients with low-risk and intermediate-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. <i>Cancer</i> , 2015, 121, 876-882.	4.1	93
255	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.8	69
256	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015, 125, 3236-3245.	1.4	113
257	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 504-510.	4.1	33
258	Sorafenib and novel multikinase inhibitors in AML. <i>Lancet Oncology</i> , The, 2015, 16, 1582-1583.	10.7	7
259	Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 279-280.	1.3	6
260	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555.	10.7	245
261	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> ,the, 2015, 2, e376-e383.	4.6	86
262	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1099-1110.	10.7	249
263	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. <i>Haematologica</i> , 2015, 100, 1058-63.	3.5	46
264	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , 2015, 39, 1367-1374.	0.8	48
265	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2541-2541.	1.4	7
266	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2015, 126, 461-461.	1.4	9
267	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. <i>Leukemia Research</i> , 2014, 38, 1126-1129.	0.8	29
268	Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e115-e118.	0.4	27
269	Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3671-3671.	1.4	3
270	Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. <i>Blood</i> , 2014, 124, 389-389.	1.4	86

#	ARTICLE	IF	CITATIONS
271	Treatment of Hairy Cell Leukemia During Pregnancy: Are Purine Analogues and Rituximab Viable Therapeutic Options. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 86-89.	0.4	21
272	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966.	4.1	46
273	Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. <i>Leukemia Research</i> , 2013, 37, 1440-1444.	0.8	25
274	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013, 121, 4655-4662.	1.4	355